Category: News

cdp-web_bourn-quarter

Cambridge Design Partnership invests in its future, and in its commitment to client outcomes

July 16th 2026

Nigel Hall’s appointment as Chair marks an investment in CDP’s future: in the clients it serves, the employee owners who own the business, and the next stage of its growth.

 

Cambridge Design Partnership (“CDP”) has appointed Nigel Hall as Chair, effective 6 July 2026. The appointment is another step in the development of CDP’s board and leadership team, following the appointments over the past year of Wade Tipton as Chief Executive Officer, Chris Jones as Chief Financial Officer and Board Director, and Corey Smigelski and Michael Zeitlyn to its international leadership team.

Nigel-Hall

Nigel Hall – Non-Executive Chair of the Board

The appointment comes as CDP, a 100% employee-owned product development consultancy working across the US and Europe, invests in a simple conviction: that clients are best served by partners who genuinely care about their success. At CDP, every member of the team owns a share of the business, so when a client wins, its people win too. It is a model the firm believes turns a supplier into a trusted advisor.

Nigel Hall brings more than 30 years of international leadership in building, scaling and transforming international innovative, technology-led businesses. His career spans senior roles at Orange and KPMG, the leadership of Cambridge Broadband Networks, and a range of board, advisory and investment roles with growth companies. It is precisely this experience in transformation and disciplined growth, that maps to the journey CDP is on.

His appointment reflects the latest in a deliberate evolution of experienced hiring. In the period leading up to it, Nigel has worked closely with CDP’s CEO Wade Tipton, on CDP’s strategy and the plan to deliver it, supported the leadership team through a significant transition, and helped put in place a clear agenda for change designed to leave the business well placed for future growth. Formalising his role as Chair gives that work long-term stewardship at board level, independent challenge and experience to a leadership team entering its next phase in growth.

Nigel Hall said: “What drew me to CDP is something you rarely find: world-class engineering and science combined with genuine ownership. When the people solving a client’s hardest problem also own the business, they care about the outcome in a way that cannot be manufactured. That is the foundation of a trusted advisor. CDP has reached exactly the right moment to build on it, and I am delighted to help the people and teams at CDP do so.”

"When the people solving a client’s hardest problem also own the business, they care about the outcome in a way that cannot be manufactured."
Nigel Hall

CDP’s strengthened board will bring sharper governance to their client promise: to accelerate product development, navigating risks and increasing their chances of success, with a partner whose own success is tied to theirs. Part of Nigel’s role will be to help the leadership team stay true to that client proposition. For CDP’s employee owners, it signals a business investing in the future they collectively own. A more experienced board, a clear plan for growth, and a stronger platform for the careers, capabilities and rewards that employee ownership is designed to share.

Nigel added: “My job is to help Wade and the leadership team stay true to what makes CDP special as it grows. We have a clear strategy and a practical plan to deliver it, and the timing is right: the foundations are in place, and the opportunity to help clients succeed has never been greater. Good governance combined with experienced people will make that ambition more achievable.”

“Nigel understands what makes CDP different. We are here to help our clients succeed, and because we own the business, we care about that success as if it were our own.”

Wade Tipton | CEO

Wade-Tipton_thought-leadership

Wade Tipton, Chief Executive Officer, said: “Nigel understands what makes CDP different. We are here to help our clients succeed, and because we own the business, we care about that success as if it were our own. Over recent months Nigel has worked closely with me on our strategy and the plan to deliver it, and helped steady the team through a period of real change. Formalising his role as Chair gives that work the long-term stewardship it deserves, and I am delighted to welcome him.”

CDP’s promise to its clients is a simple one: to be the partner they trust with their hardest problems, and to care about the outcome as much as they do.

|||

CDP advances surgical robotic technology

March 11th 2025

In collaboration with CDP, Titan Medical has unveiled its next-generation technology for single-access robotic-assisted surgery (RAS).

End-to-end product development partner Cambridge Design Partnership (CDP) assisted Titan Medical in designing and developing the next-generation technology for single-access RAS.

In a short time, a diverse CDP team of systems engineers, human factors specialists, industrial designers, and mechanical, electronics, and software engineers collaborated with Titan Medical to propel the development from initial concept to advanced prototype. The project is the latest example of CDP’s work in high-impact innovation in complex medical devices embodying the company’s mission to improve lives through innovation.

The Head of Robotics at CDP, says, “The starting point for this next-generation technology was the remarkable core innovations and intellectual property that power Titan Medical’s two-instrument Enos system. Titan Medical’s articulating instrument technology provides an impressive balance of dexterity and strength, allowing the surgeon to precisely maneuver them to achieve procedural tasks like grasping, suturing, and cutting. Similarly, Titan Medical’s 3D high-definition camera provides crystal clear visibility for the surgeon to be able to see the surgical site. We built on these core technologies, adding functionality for a third instrument and focusing on the usability, performance, and reliability of a RAS system.”

Cary G. Vance, President and CEO of Titan Medical, says, “CDP, with their proven record in innovation, enabled us to quickly unlock the value of our IP and convert our purpose-driven innovations and inventions into functioning prototypes. CDP has been a key partner through the years, delivering timely, high-complexity, and top-notch work. We are excited to share this achievement with them.”

By enabling surgeons to perform procedures through a single incision, Titan Medical’s technologies have the potential to reduce patient trauma and scarring and could enable patients to recover faster. This next-generation technology introduces advanced new features, such as software-enabled remote center of motion, and adds a third dexterous instrument to allow greater procedural flexibility and enhanced surgeon control. Innovations in the design allow a more compact footprint and lighter weight than current systems, taking up less space, making it easier to maneuver in space-constrained operating rooms, and providing open access to the patient.

The Head of US Office at CDP, adds, “Ultimately, the focus needs to be on the patient and on enabling the surgical team to achieve the most successful surgical outcomes safely and effectively. A key insight that fed into this development was recognizing that many RAS systems crowd the bedside and impede access to the patient. Sometimes you can barely see the patient under the robotic arms! We saw an opportunity to create a patient cart with a minimalistic and open architecture that is easy to work with and work around. Our work in advanced medical devices, particularly RAS technologies, continues to be one of the highlights of CDP’s 27-year history. This milestone is a proud moment for us, and we believe this technology will be a benchmark for single-access surgery.”

Concluding that, “Designing highly capable RAS systems means carefully navigating challenges and compromises such as performance and safety. Our approach resulted in an advanced and simple-to-use system that finely balances those difficult compromises. We delved deep into Titan Medical’s extensive intellectual property portfolio to be able to develop the best of all available technologies and bring our client’s valuable know-how to life. When working with CDP, our clients get access to our proven history of innovation, our nimble processes, and highly capable teams. This project is a great highlight of our capabilities embodied in one deliverable.”

“CDP has been a key partner through the years, delivering timely, high-complexity, and top-notch work. We are excited to share this achievement with them.”

Cary G. Vance, President and CEO of Titan Medical

GET IN TOUCH
|CDP - Featured in The Times

Bringing Innovation to Life

June 6th 2024

Cambridge Design Partnership was recently featured in The Times with our Co-Founder Matt Schumann and Head of Mechanical Engineering Stuart Curtis discussing how our innovative solutions are helping clients speed up time to market and enhance the lives of those they serve.

CDP - Featured in The Times

 

 

 

READ IN FULL
LEARN MORE

The World’s First Touchable Memory.

A Device Shining a Light on Usher Syndrome

Learn more about our involvement in the remarkable Usher syndrome awareness campaign.

READ MORE
|CDP - Featured in The Times

Introducing the World’s First ‘Touchable Memory’: A Device Shining a Light on Usher Syndrome

April 2nd 2024

We are honored to announce our involvement in a remarkable awareness campaign with Cure Usher, Havas Lynx, and Push Films: the world’s first ‘touchable memory’ device.

This awareness campaign seeks to shed light on Usher syndrome, a genetic condition that causes varying degrees of hearing and sight loss from an early age. Despite its significant impact, Usher syndrome remains underrecognized, with a misdiagnosis rate of 40%, underscoring the critical need for heightened awareness and understanding.

Our collaboration on this project perfectly encapsulates our commitment to improving lives through innovation.

By developing a device to appear in the campaign film that converts sounds into tactile sensations, we enabled the campaign’s real-life sisters – Laura, who has Usher syndrome, and Hannah – to reconnect with a memory in a uniquely inclusive manner.

We invite you to watch the emotional film and explore the press release below.

https://youtu.be/SQXHR3sfoZw?feature=shared

 

The World’s First Touchable Memory. A Device Created To Raise Awareness About This Impairing Genetic Condition

  • Usher syndrome is a genetic condition that develop in children and young adults causing the loss of hearing and sight in different degrees.
  • Awareness of Usher is low with doctors misdiagnosing 40% of the time leading to uncertainty for families. In the UK around 11,000 people have been diagnosed with Usher, with an estimated 400,000 people worldwide.

Cure Usher Syndrome, a patient-led charity dedicated to raising awareness of Usher Syndrome, has launched its new brand awareness initiative, kicking off with an emotional short film which shows two sisters experiencing the world’s first touchable memory.

Conceived by leading global healthcare communications agency, Havas Lynx, and transformed into a real device by tech-experts, Cambridge Design Partnership, the device transforms stimuli such as sound or music, into tactile sensations. The frequency of these vibrations is adjusted for the hand’s receptors, which research shows can detect almost nothing over 1,000Hz.

The emotional short film features Laura Whitaker, a woman who has lived with Usher syndrome since a young age and her sister Hannah Stroud. It shows the real-life sisters interacting with the ‘Touchable Memory’, which allows them to experience a moment in time the same way despite Laura’s hearing and sight limitations.

In preparation for the film, Laura and Hannah undertook a series of interviews which allowed the Havas Lynx team to collate information to select a memory to hide in the device.

Not only does the device translate sounds into vibrations, but it was also designed with a specific shape, light, and colour for people with limited concentric sight.

Stuart Curtis, Engineer at Cambridge Design Partnership, said: “Results showed that skin receptors on the hands respond best to low-frequency sound and can detect almost nothing over 1,000Hz compared to our hearing which can detect 20,000Hz. With the use of surface transducers, we translated a synthetic baseline from a MIDI track, into a sensorial experience. These frequencies became physical and allowed Laura and Hannah to feel the music rather than hear it.”

Alex Okada, Chief Creative Officer at Havas Lynx, said: “Since this condition is still incurable, we had to be very careful how to raise awareness without spreading fear. The device was a way to grab attention but the emotional connection between the sisters was what made it meaningful.”

Mark Jordon and Laura Norton are Patrons at Cure Usher Syndrome, they have two young children who both have the condition. Talking about the campaign, both said: “We are proud and privileged to be joint patrons of Cure Usher, and to support this charity in raising awareness of Usher syndrome.

“The film is unbelievably powerful, I think it is going to have a huge impact in raising awareness of usher syndrome and what it means to find a cure. The human element of Laura and Hannah’s story is invaluable, and I can’t thank them enough for sharing their memories and the power that their story holds.

“A huge thanks also to Havas Lynx, Cambridge Design Partnership, and Push Films, all bringing the magical elements to make this emotional film.”

Cure Usher Syndrome is working to raise awareness, support families and raise money for vital medical research. It currently has an agreement with University College London (UCL) where donations directly fund research as part of the Institute of Ophthalmology.

You can donate to Cure Usher Syndrome via its website: https://cureushersyndrome.com/donate-support/

For more information contact: robyn.houghton@havas.com

Femography and Cambridge Design Partnership

Collaborating to improve lives through innovation

October 18th 2023
Abby Scheer

Abby Scheer 

Consultant Industrial Designer

Martha Hodgson 

Over the last few years, Cambridge Design Partnership (CDP) has developed a strategic partnership with MAS Holdings, South Asia’s largest apparel tech company.

Our most recent collaboration has been with Femography, the FemTech division of MAS Holdings, which started out as a small team with diverse expertise, and has evolved into the FemTech arm of the Company. Femography leverages 35 years of apparel tech expertise and works with some of the world’s biggest brands to create innovative apparel solutions that focus on addressing the unseen and unmet needs of women. These innovative solutions are breaking taboos through their textile technology and mission-led practices. The partnership between CDP and Femography combines ingenuity and cross-disciplinary approaches to rapidly create and expand access to impactful women’s health solutions.

Our partnership with Femography was focused on the identification of white space opportunities within menstruation. This leveraged our combined passion and commitment to innovation within the women’s health space. The outcome resulted in a creative solution pipeline which has extended and elevated Femography’s product pipeline.

In this article, Abby Scheer, an Industrial Designer and FemTech Lead at CDP, reflects on the importance of strategic partnerships with Femography’s Tehani Renganathan and Ginnymarie Mendis, and shares exciting key learnings for successful innovation across the FemTech space.

The role of strategic partnerships in successful FemTech innovation

Strategic partnerships provide multi-faceted value, especially in driving innovation that helps transform lives. The partnership between CDP and Femography includes a shared vision that challenges taboos and pre-existing social norms surrounding the female body and increases the discovery and development of impactful solutions.

“We partnered with companies and consultants who really shared that vision, they were vested in this journey with us – and it is that success that we see the fruit of today.” – Tehani Renganathan, Chief of Strategy, Marketing and New Ventures, Femography

Backed by science and approved by women, Femography designs everyday lifestyle solutions across all phases of the feminine journey – from menarche to menopause and everything in-between. Femography’s solutions are created to help women live confidently in their bodies, but many taboos continue surrounding feminine health and well-being.

“Our efforts aren’t focused on creating just a regular clothing/apparel solution, but to also look at solving unmet and undermet needs of our consumers. We have understood the many pain points they journey through, and we are continuously working towards giving them a passive or active solution that can restore normalcy for them.” — Ginnymarie Mendis, Chief of Consumer and Product Innovation, Femography.

Strategic collaborations with insightful partners increase the breadth and depth of discovery and development of impactful solutions – this is especially important in the FemTech space where research and funding is often lacking. Femography approached CDP for expertise in the consumer health and technology space, and together we met this menstrual health challenge head-on.

Building a successful strategic partnership

Drawing on her firsthand experience, Ginny shared how a successful partnership should have “…mutual trust, respect, and a shared vision and commitment to the journey”. When it comes to innovation, it is also important to have a creative partner who can help bring early ideas and concepts to life as fast as possible. CDP’s innovation, efficiency, and approach were a foundational aspect of the partnership formed between CDP and Femography.

“We wanted to bridge our strengths with your [CDP’s] strengths and come up with even greater solutions and innovations that could really have an incremental impact on our planet” – Ginnymarie Mendis.

Femography also recognizes that strategic partnerships are key to successfully expanding its existing portfolio into everyday periodwear and even period swimwear in a meaningful way. When looking to expand into new customer markets across, for example, US, EU, Australia, and Asia, fine-tuning product categories is key.

The FemTech knowledge, cross-cutting sector expertise, and user-centered design approaches which CDP brings to their strategic partnerships has helped to unlock how existing solutions can meet users’ needs and support the rapid discovery of transformative solutions for growing women’s health issues.

New innovation opportunities in FemTech apparel

Reflecting on our recent collaboration, Tehani highlighted the exciting and anticipated new opportunities which can be created and unlocked due to our partnership.

“The CDP and Femography partnership will help create and unlock access to non-medical alternatives to help women better manage their health. An important objective includes exploring a broad product landscape, creating a pipeline of global solutions mapped to symptoms and other pain points women struggle with.” -Tehani Renganathan.

Equally, Tehani reflected on a fantastic launch that the Femography team is exceptionally proud of. Become, the consumer-facing menopause brand of Femography that was launched in the UK almost 7 years ago, was transformational in helping to get the menopause conversation started. Become frequently partners with other brands and organizations to lead change, providing another great example of the importance of innovation collaborations. This year Femography has expanded the Become footprint to the US market to leverage American women’s vocal conversations on menopause, increase awareness of the topic, and provide a solution to women who need it.

What next?

Much more work is still needed to address the health needs of women in the UK and US, and even more so in many developing and underprivileged communities. The collaboration between CDP and Femography continues to help innovate and expand the reach of unique solutions in women’s health across each sub-sector market. Together, CDP and Femography will strive to collaboratively innovate meaningful products, to help bring greater health, dignity, and confidence to all feminine bodies.

Re-Vana Therapeutics enters collaboration with CDP

Re-Vana Therapeutics enters collaboration with Cambridge Design Partnership

October 12th 2023
Cambridge Design Partnership

Cambridge Design Partnership 

Re-Vana Therapeutics enters collaboration with Cambridge Design Partnership on development of novel delivery system for OcuLief®, an in-situ forming implant for the sustained release of biologic ophthalmic formulations.

Re-Vana Therapeutics Ltd, a venture-backed and privately-held specialty therapeutics and drug delivery enterprise focusing on sustained-release treatments for severe ocular conditions, has teamed up with a top-tier product and technology design firm, Cambridge Design Partnership. Together, they aim to create an innovative delivery system for OcuLief, Re-Vana’s gel-based implant that forms in-situ for extended biologic delivery.

Re-Vana’s innovative technology platforms are capable of delivering both novel and approved biologics for a minimum of 6 months clinically. This diminishes the demand for burdensome, regular intravitreal injections and amplifies the therapeutic effect for significant ocular conditions. The delivery mechanism allows for a minimal dose of the OcuLief gel through a non-invasive, standard intravitreal injection in an office setting. This gel evolves into a tiny bleb, which then converts into a degradable implant using focused, pulsed visible light, ensuring prolonged release of treatments at high release rates into the eye.

Patrick H. Ruane, Ph.D., Chief Operating Officer of Re-Vana Therapeutics, remarked, “Re-Vana’s OcuLief technology has shown enormous potential in sustained release of biologics delivered via intravitreal injection, for example for neovascular Age-related Macular Degeneration (AMD) and Diabetic Macular Edema (DME), a highly competitive market with more than $15 billion in annual sales. Transitioning OcuLief’s delivery system from a prototype to a tool suitable for pre-clinical and clinical evaluations is vital for its success. We sought a dynamic, innovative partner possessing the diverse skills and experience necessary for a seamless progression from our labs to a market-ready solution. The advancements we are achieving with Cambridge Design Partnership are noteworthy, and their team’s collaborative spirit greatly impresses us.”

“When we started talking with the Re-Vana team, we immediately found their technology and its potential very compelling,” commented Clare Beddoes, Head of Drug Delivery, Cambridge Design Partnership. “Our in-house capabilities in the Drug Delivery sector enable us to accelerate time to market for companies like Re-Vana Therapeutics, reducing the need to work with multiple vendors throughout the development of complex and advanced delivery systems. That Re-Vana Therapeutics chose us as their development partner is testament to our experience in supporting the development of combination products, and the skills of our team in tackling the complex challenges and achieving hugely successful results. Re-Vana will also benefit from the addition of our new Pilot Production Centre and our in-house manufacturing capabilities, features that resonate with the needs of our customers.”

For further details, join Patrick H. Ruane, Chief Operating Officer of Re-Vana Therapeutics, as he presents at the “Partnerships in Drug Delivery” conference in Boston, MA, October 16-17. Dr. Ruane is scheduled to share insights during the “Cell, Gene, and other Biologics” session from 4:15 to 6:30 p.m. on October 16th.

About Re-Vana Therapeutics

Re-Vana Therapeutics is venture backed, pioneering therapeutics and ocular drug delivery company focused on the development of innovative sustained-release biologics to treat serious diseases of the eye using its proprietary photo-crosslinking technology. The company’s innovative platform technologies, EyeLief®, EyeLief SD™ and OcuLief®, enable the tunable delivery of biologics and small molecules, creating a therapeutic continuum to expand global treatment opportunities through both internal development and external, strategic collaborations. Re-Vana envisions a new industry standard of 6-12 months delivery of biologics to the retina to create transformative and differentiated treatments for patients and their physicians.

About Cambridge Design Partnership

Cambridge Design Partnership is an end-to-end innovation partner, propelling global brands and ambitious start-ups to success. We build breakthrough products and services – from insight to ideas, prototypes to production – bringing innovation to life. Our teams are multi-disciplinary, uniting scientific rigor, design ingenuity, and engineering excellence for consumer, healthcare, and industrial clients. People-centered, deeply collaborative, and – above all – expert, we’re uniquely positioned to shape the future for consumers, patients, and industry. Even our ownership model is innovative: We’re 100% owned by our employees, ensuring an open culture and a total commitment to your project’s success. One partner. No barriers. Extraordinary results. For more information, please visit www.cambridge-design.com

Connect with CDP

To find out how CDP can accelerate the development of complex ophthalmic and sustained-release drug delivery systems, contact Cambridge Design Partnership.

Get in touch
|

Cambridge Design Partnership and CPI launch the UK’s In Vitro Diagnostics Roadmap

January 11th 2023

Cambridge Design Partnership and technology innovation catalyst CPI today launch A Strategic Technology Roadmap for the UK In Vitro Diagnostics Industry, a major new report for industry leaders, government, and the UK’s health tech companies.

The UK in vitro diagnostics (IVD) industry has the potential to help boost UK economic growth and make the UK a global leader in the industry while improving health in the UK and for people worldwide. A new strategy, applied over the next 10 years, can see the industry transformed. The Roadmap, researched and written by Cambridge Design Partnership, in partnership with CPI, the Association of British HealthTech Industries (ABHI), and funded by Innovate UK, defines the key technologies and strategies that can place the UK at the forefront of this industry.

In vitro diagnostics – analysing biological samples outside of the body to determine health status – shows huge promise, from earlier cancer detection to the prevention and management of infectious and chronic diseases. The UK is already a global leader for science and technology. Many of the technologies at the heart of this thriving industry were pioneered in the UK, from lateral flow tests to the genetic sequencing technology used in around 80% of the world’s genetic sequencing systems. But the UK is not at the top table of the growing IVD industry, with recent estimates suggesting it accounts for just 3% of a £90bn industry. While the UK excels at research, it is held back by the commercialisation process. As a result, many UK inventions are commercialised by overseas companies – start-ups and scale-ups are acquired by global leaders, and we are yet to see the emergence of major UK IVD companies or state-of-the-art R&D centres from the global industry.

A Strategic Technology Roadmap for the UK In Vitro Diagnostics Industry sets out a programme of change to help meet the clinical needs of the future and support the UK IVD industry, government, and Innovate UK to make informed investment and capability development decisions. This Roadmap is a resource for:

  • Companies planning their strategies over the medium to long term, particularly leaders in medical technology, the pharma industry, and the investment community that supports them
  • Policy makers and broader government stakeholders shaping future UK government strategy and funding decisions
  • All those interested in and charged with the success of UK PLC.

Pari Datta, Principal Consultant in Strategy at Cambridge Design Partnership and the Roadmap’s lead author, says, “It’s hugely encouraging that the UK continues to lead the science behind all the major opportunities for the IVD industry – just as it did before for lateral flow testing and DNA sequencing. But we’ve yet to create global IVD industry leaders of our own or attract investment in UK R&D from global IVD leaders. Our strong position in research means we can change that. We can become one of the global IVD leaders of the future, boosting national economic growth and taking a global leadership role while improving patients’ lives worldwide.”

The Roadmap is part of the Health Technology Regulatory and Innovation Programme, an Innovate UK-sponsored initiative led by CPI in partnership with ABHI. This programme delivers a package of support to UK health tech companies to help them meet the regulatory requirements for developing, commercialising, and deploying their medical technology in the UK and globally.

A second report – Challenges and Opportunities for the UK HealthTech Industry – was also published today. For this report, CPI and ABHI worked with over 350 small-to-medium-sized enterprises (SMEs), Innovate UK and health tech stakeholders to identify the key challenges faced by the UK health tech SME community.

Dr Arun Harish, Strategy Director at CPI, said: “As a Catapult centre leading on HealthTech in the UK that works with many health SMEs in the sector, we understand how hard they find the navigation of the regulatory approvals process and the route to commercialisation. These two first-of-their-kind reports will help industry, policymakers, government, funding agencies and the wider HealthTech ecosystem immensely with shaping future interventions to grow the HealthTech industry in the UK. They also highlight the need for further intervention to support UK HealthTech businesses in developing and scaling-up innovative technologies, which will ultimately benefit UK populations.”

Selected Roadmap highlights

  • The Roadmap begins by defining a shared vision, acting as a focal point for stakeholders involved in the project and those going on to implement and follow the Roadmap. The vision statement is: “The UK will be the industry nucleus for world-leading businesses, with the resources, skills, and proven pathways for advancing pioneering technologies into successful data-enabled IVD solutions.”
  • Using oncology and infectious diseases as key disease states, input was collected from clinicians, publications, and patents to define nine key technology-enabled opportunities for the global IVD industry over the next 10 years. These are:
    1. Digital PCR
    2. Sequencing
    3. Cell-free nucleic acids
    4. Digital biomarkers
    5. Proteomics
    6. Combined biomarkers
    7. Single cell analytics
    8. Exosomes
    9. Metabolomics
  • The report recommends that the UK develops specific technologies in materials, enzymes, artificial intelligence (AI)/data, optics, microfluidics, and sensors. To advance in these opportunities, the IVD industry also needs to build collaborations with companies that have expertise in these areas.
  • Seven major challenges are identified that must be resolved, including lack of UK infrastructure and ecosystem for design and development, acquiring patient samples, clinical studies, commercialisation, adoption, clinical reimbursement, and financing and investment.
  • In conclusion, the report recommends that the UK needs to adopt the following strategies to overcome these challenges and realise its vision for the UK’s IVD industry:
    • Boost the IVD industry’s profile in the UK
    • Create a focused government-led strategy for the UK IVD industry
    • Support access to NHS resources during development and commercialisation
    • Assist IVD companies through a well-defined and harmonised regulatory pathway
    • Develop partnerships for high-risk IVD developments that have defined pathways to clinical use

Download the In Vitro Diagnostics Roadmap

For further information and media enquiries, please contact: media@cambridge-design.com or call 01223 264428.

|||||

CDP launches CDP Mosaic: Accelerating your digital journey 

September 13th 2022

Cambridge Design Partnership has built a new digital ecosystem catalyst to accelerate clients’ digital products to market. CDP Mosaic propels digital products through rapid conceptualization, prototyping, development, and global deployment – into the hands of consumers and patients.

CDP Mosaic offers pre-built, customizable front-end, flexible UX/UI design elements, cloud-agnostic back-end architecture, third-party integration-ready infrastructure, and built-in data science tools. These core facilities are fundamental to digital ecosystems and stand ready to be tailored to clients’ needs.

LEARN MORE

Head of Software, Data & Digital, Rupert Menzies, says: “Digital development is different. Best practices that are tried and tested for traditional product development don’t bring the same benefits to digital development. This can leave you with a digital product that’s prohibitively expensive to operate and maintain and limits your flexibility for the future without starting again from scratch. CDP Mosaic allows you to flex to the fast-moving digital landscape and deliver user benefit rapidly.”

“CDP Mosaic allows you to flex to the fast-moving digital landscape and deliver user benefit rapidly”

Rupert Menzies, Head of Software, Data & Digital

Working in close partnership with clients, the team uses CDP Mosaic to build a digital ecosystem to meet clients’ unique needs. Bring your own device, bring your own data, pick your own cloud – easy integration is part and parcel of CDP Mosaic. Clients can own the data and the tailor-made product.

CDP Mosaic’s modules are informed by consumers’, patients’, and industry’s most prevalent needs. Innovative, commercially powerful applications for CDP Mosaic include:

  • digital therapeutics
  • remote, real-time clinical trial monitoring
  • digital biomarkers
  • smart manufacturing
  • Internet of Things (IoT)
  • smart packaging
  • sustainability and circularity
  • point-of-care diagnostics
  • remote monitoring and diagnostics

CDP Mosaic is already being applied to enable solutions driven by data science, including passive screening for polycystic ovary syndrome (PCOS) and predictive failure analysis to optimize maintenance processes.

Digital Lead, Stephen Zabrecky, says: “CDP Mosaic is designed to be a solid foundation for building any digital ecosystem. You can think of it as the building blocks for a house, an apartment block, or even a stadium – it’s completely scalable.”

CDP Mosaic will be presented at DPHARM, Boston, on September 13-14, 2022. 

For more information on CDP Mosaic, visit CDPMosaic or email CDP.Mosaic@cambridge-design.com. 

||

CDP unlocks solar EV charging innovation

July 8th 2022

Collaboration between 3ti Energy Hubs and Cambridge Design Partnership propels pop-up, mini solar car park and EV charging hub to launch ahead of crowdfunding campaign.

End-to-end innovation partner Cambridge Design Partnership (CDP) has helped the UK’s leading solar car park company, 3ti, create Papilio3, a pop-up mini solar car park and EV charging hub. Papilio3 will advance the rollout of EV charging infrastructure, helping decarbonize the mobility sector and supporting the global transition to net zero.

Papilio3 is the latest example of CDP’s work in high-impact innovation in renewables, EV charging, and energy infrastructure. The CDP team of industrial, mechanical, and product design engineers collaborated closely with client 3ti – from concept development and visualization to product engineering and realization. CDP supported 3ti in building the supply chain for the pop-up mini solar car park, which is built around a recycled shipping container and combines solar electricity generation, battery energy storage, and EV charge points.

CDP’s Head of Industrial, James Baker, says: “We’re proud to work with start-ups and scale-ups, like 3ti, addressing the biggest challenges. Helping companies innovate and develop new businesses in infrastructure is key to decarbonization. Papilio3 addresses renewables infrastructure with a much-needed, easy-to-deploy, and cost-effective approach.”

3ti’s Founder and CEO, Tim Evans, adds: “From our very first meeting, CDP understood and shared our vision for Papilio3. We’ve worked in close partnership over 12 months to get to this exciting point. We’re now focused on commercialization and plan to have units available to roll-out across the UK by Autumn. CDP built a talented, multi-disciplinary team addressing our mechanical brief, and delivered our first prototype designs at speed. Working with an end-to-end innovation partner like CDP has proved to be a wise decision. Since launching Papilio3 on May 26, 2022 the response has been phenomenal, with enquiries from around the world. Our crowdfunding campaign, designed to fund the roll-out of Papilio3, exceeded its target of £500,000 within 24 hours and we’ve taken the decision to overfund to make the most of this opportunity. I’d like to thank the team at CDP for being a key part of the project.”

“From our very first meeting, CDP understood and shared our vision for Papilio3. We’ve worked in close partnership over 12 months to get to this exciting point.”
Tim Evans
3ti’s Founder and CEO

Papilio3 makes charging accessible to EV drivers who can’t charge at home, providing destination charging in places without existing infrastructure, including offices, retail outlets, and leisure facilities. Made in the UK, Papilio3 is assembled from recycled shipping containers and provides 12 EV charge points under a waterproof solar panel canopy. The pop-up mini solar car park is designed for swift and straightforward deployment. Installation takes under 24 hours, with minimal site works, no new grid connection, and with no need for planning permission in most instances. The units are available to rent from 3ti, avoiding up-front costs or long-term commitments.

The first unit was installed at Surrey Research Park, Guildford, hosted by the University of Surrey, in May 2022, ahead of the launch of 3ti’s crowdfunding campaign. 3ti is crowdfunding to support their rapidly growing business, which is focused on generating clean, renewable energy today, for everyone’s tomorrow. By becoming a shareholder in 3ti, investors will be supporting the UK’s switch to electric vehicles and the decarbonization of the mobility sector.

To register your interest in contributing to the 3ti is hosting two Investor Days at Surrey Research Park on Wednesday, July 6, and Friday, July 15. Book your free ticket using Eventbrite.

Visit their site for more information. Capital at risk.

For further information and media enquiries, email media@cambridge-design.com or call +44 (0)1223 264428.

web_hero_CDP-CPI-technology-roadmap-for-UK-in-vitro-diagnostics

Work begins building a new capability roadmap for the in vitro diagnostics industry

April 26th 2022

In collaboration with deep tech innovation partner CPI and supported by Innovate UK, Cambridge Design Partnership is constructing a new actionable capability and technology roadmap for the in vitro diagnostics industry.

The in vitro diagnostics (IVD) industry makes up the largest part of the life sciences sector, one of the UK’s dominant economic markets. The COVID-19 pandemic has underscored the IVD industry’s importance. An aging population, increasing prevalence of chronic disease, advancements in personalized medicine and genomics, and the decentralization of healthcare are all fueling the fast growth of the IVD market, delivering opportunities for the UK economy and internationally.

To be published in late 2022, the roadmap will deliver a strategic plan centered on clinical, commercial, and technical insights through close collaboration with clinicians, businesses, industry bodies, technical experts, and other stakeholders in the IVD ecosystem. To help meet the clinical needs of the future, the roadmap will support the UK IVD industry, Government, and Innovate UK to make informed investment and capability development decisions.

At the same time, the UK’s regulatory landscape for healthcare technology is changing. The Medicines and Healthcare products Regulatory Agency is currently consulting on the UK’s future regulation of medical and IVD devices – and manufacturers will need to be prepared to react.

The roadmap will be published as part of the Health Technology Regulatory and Innovation Programme, an Innovate UK sponsored initiative, led by CPI in partnership with the Association of British HealthTech Industries. This programme is delivering a package of support to UK health technology companies to help them meet the regulatory requirements for developing, commercializing, and deploying their medical technology in the UK and globally.

CPI will bring to the project its specialist skills and capabilities in healthcare technology development along with its wide-reaching connections across regional and national healthcare networks. The organization works with companies across the health technology space to provide support with disruptive innovation, process development, and scale-up to drive the next generation of IVD devices.

End-to-end innovation partner Cambridge Design Partnership (CDP) helps its healthcare clients bring new products and technologies to market. Its experienced diagnostics team has a rich track record in all stages of development, from identifying market insights and concept generation to assay implementation and manufacturing scale-up.

In building the roadmap, CDP will lead virtual and in-person workshops with healthcare providers, regulators, technology market leaders, and other stakeholders to understand the value and challenges linked with opportunities and technologies.

Pari Datta, Senior Innovation Consultant at CDP, says, “We’re looking forward to helping the IVD industry realize its potential. It’s a unique moment for the industry, experiencing significant investment and seeing extraordinary innovation. Against the background of COVID-19 and the emergence of new ways of delivering healthcare, we’re eager to play our part in enabling the UK to become a global leader in IVD – we hope the roadmap will guide the UK in developing technologies to enable new businesses of the future.”

Dr Arun Harish, Strategy Director at CPI, says, “We are excited to be working with CDP to develop and deliver the IVD roadmap to help industry and academia make informed decisions on their research, development, and innovation agenda. This roadmap will also contribute to the UK IVD industry’s growth across supply and value chains, and the delivery of substantial societal and economic impact.”

Centered around incremental, disruptive, and future opportunities for the IVD industry, the roadmap will be supported by an analysis of the challenges attached to the technologies featured – and the steps needed to fulfill a ten-year vision for the diagnostics industry.

To register your interest in contributing to the project or receiving the roadmap on publication, email Pari Datta, Senior Innovation Consultant at CDP: pari.datta@cambridge-design.com.

For further information and media enquiries, email media@cambridge-design.com or call +44 (0)1223 264428.